Comparison of pioglitazone and linagliptin

Comparison of the effects of pioglitazone and linagliptin on glycemic control, lipid profile, and hs-CRP in patients with type 2 diabetes mellitus under treatment with metformin

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N66

Enrollment

Registered

2019-10-28

Start date

2019-09-23

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group1: 30 mg pioglitazone (osveh pharmaceutical company, Tehran, Iran) daily, for 3 months orally. Intervention 2: Intervention group2: 5 mg linagliptin (Alhavi pharmaceu

Eligibility

Sex/Gender

All

Age

30 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with type 2 diabetes Individuals aged 30-50 years old FBS =140 under treatment with metformin for at least 3 months

Exclusion criteria

Exclusion criteria: Secondary diabetes due to cushing syndrome, acromegaly and other diseases systemic inflammatory diseases such as rheumatoid arthritis, IBD, vasculitis, etc. renal or liver or heart failure malignancy under insulin therapy pregnancy unwillingness to cooperate

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose levels. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.	—

Secondary

Measure	Time frame
HbA1c. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: HPLC.;Total cholesterol. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein (HDL) cholesterol. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.;Low-density lipoprotein (LDL) cholesterol. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Elisa kit.;Weight. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: scale.;Systolic and diastolic blood pressure. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: sphygmomanometer.	—

Measure

Time frame

HbA1c. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: HPLC.;Total cholesterol. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein (HDL) cholesterol. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.;Low-density lipoprotein (LDL) cholesterol. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: Elisa kit.;Weight. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: scale.;Systolic and diastolic blood pressure. Timepoint: At the beginning of the study and after 3 months of intervention. Method of measurement: sphygmomanometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shadi yazdani

Kashan University of Medical Sciences

Dr.yazdani.shadi@gmail.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026